Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathway Enrichment Analysis of Whole-Exome Sequencing Data from Formalin-Fixed, Paraffin-Embedded Enucleated Eyes with Retinoblastoma and Choroidal Malignant Melanoma.

Cureus·2026
Same author

A Biologically Dominant Trophoblastic Component Guiding Neoadjuvant EMA/CO in Endometrial Carcinoma: A Clinical Case Report.

Clinical case reports·2026
Same author

Factors that delay discovery in cases of death at home in Japan.

Legal medicine (Tokyo, Japan)·2026
Same author

The association between hyponatremia and immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy.

Transplantation and cellular therapy·2026
Same author

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026
Same author

Association of ideal body weight-normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Sep 13, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K

Real-World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma.

Eiji Nakata1, Daisuke Ennishi2, Tatsunori Osone3

  • 1Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

Cancer Medicine
|August 4, 2025
PubMed
Summary
This summary is machine-generated.

Comprehensive cancer genomic profiling (CGP) using dual DNA-RNA panels improves sarcoma diagnosis and treatment selection. Genotype-matched therapies demonstrate improved outcomes and survival rates in sarcoma patients.

Keywords:
comprehensive genomic profilinggenotype‐matched therapymultiplex gene panel testsarcoma

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.1K

Related Experiment Videos

Last Updated: Sep 13, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.1K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Next-generation sequencing-based comprehensive cancer genomic profiling (CGP) aids cancer diagnosis and personalized treatment.
  • The clinical utility of CGP, particularly dual DNA-RNA panels, in routine sarcoma management under public health insurance is not well-established.
  • Limited data exists comparing DNA-RNA panels to DNA-only panels in clinical sarcoma settings.

Purpose of the Study:

  • To evaluate the utility of comprehensive cancer genomic profiling (CGP) in the routine clinical management of sarcoma.
  • To compare the efficacy of dual DNA-RNA panels versus DNA-only panels for detecting gene alterations in sarcomas.
  • To assess the impact of genotype-matched therapies on clinical outcomes in sarcoma patients.

Main Methods:

  • Utilized three DNA panels and one DNA-RNA panel reimbursed by Japanese public health insurance.
  • Detected oncogenic and druggable gene mutations and identified genotype-matched therapies for 136 sarcoma patients.
  • Analyzed diagnostic re-classification, fusion gene detection, alteration frequencies, therapy administration, and survival outcomes.

Main Results:

  • 2.2% of patients were re-classified based on histology-specific translocations.
  • The DNA-RNA panel identified more fusion genes in translocation-related sarcomas than DNA panels (p=0.0035).
  • 86.8% had oncogenic alterations, 39.0% had druggable alterations, and 9.6% received genotype-matched therapy with a 36.3% response rate and 81.8% disease control rate.
  • Genotype-matched therapy correlated with better overall survival in metastatic/advanced sarcoma patients (3-year OS: 83.3% vs. 48.0%).
  • TP53 and RB1 mutations were associated with worse overall survival.
  • Germline findings were detected in 11.0% of patients.

Conclusions:

  • Publicly reimbursed CGP, especially dual DNA-RNA panels, enhances diagnostic precision and treatment decisions in sarcoma.
  • Genotype-matched therapies demonstrate favorable clinical outcomes and improved prognosis in sarcoma patients.
  • CGP aids in detecting germline findings and predicting prognosis in routine sarcoma care.